Alphatec (NASDAQ:ATEC) General Counsel Tyson Eliot Marshall Sells 70,000 Shares

by · The Cerbat Gem

Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Free Report) General Counsel Tyson Eliot Marshall sold 70,000 shares of the company’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $19.51, for a total transaction of $1,365,700.00. Following the completion of the transaction, the general counsel owned 368,331 shares in the company, valued at approximately $7,186,137.81. This trade represents a 15.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Alphatec Stock Performance

ATEC stock traded up $0.70 during mid-day trading on Friday, hitting $20.31. 2,306,833 shares of the company were exchanged, compared to its average volume of 2,126,413. Alphatec Holdings, Inc. has a 1-year low of $8.69 and a 1-year high of $21.16. The stock has a market capitalization of $3.02 billion, a PE ratio of -17.97 and a beta of 1.17. The business has a 50 day simple moving average of $16.48 and a 200-day simple moving average of $14.17. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22.

Alphatec (NASDAQ:ATEC – Get Free Report) last announced its earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.09. The firm had revenue of $196.50 million for the quarter, compared to the consensus estimate of $182.78 million. Alphatec’s revenue for the quarter was up 30.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.28) EPS. Alphatec has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ATEC shares. Barclays boosted their target price on shares of Alphatec from $22.00 to $23.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Needham & Company LLC boosted their price objective on shares of Alphatec from $16.00 to $22.00 and gave the company a “buy” rating in a report on Friday, October 31st. Morgan Stanley raised their target price on shares of Alphatec from $16.00 to $21.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. Canaccord Genuity Group boosted their price target on Alphatec from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Finally, Wall Street Zen upgraded Alphatec from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $22.00.

Read Our Latest Report on ATEC

Institutional Trading of Alphatec

Several large investors have recently made changes to their positions in ATEC. Emerald Advisers LLC increased its stake in shares of Alphatec by 3.8% in the 2nd quarter. Emerald Advisers LLC now owns 1,684,334 shares of the medical technology company’s stock valued at $18,696,000 after purchasing an additional 60,885 shares during the last quarter. AQR Capital Management LLC boosted its stake in Alphatec by 7.6% in the first quarter. AQR Capital Management LLC now owns 676,897 shares of the medical technology company’s stock valued at $6,864,000 after buying an additional 47,939 shares in the last quarter. Northern Trust Corp boosted its stake in Alphatec by 3.4% in the first quarter. Northern Trust Corp now owns 1,049,469 shares of the medical technology company’s stock valued at $10,642,000 after buying an additional 34,726 shares in the last quarter. Voya Investment Management LLC grew its position in Alphatec by 60.1% in the first quarter. Voya Investment Management LLC now owns 49,561 shares of the medical technology company’s stock valued at $503,000 after acquiring an additional 18,605 shares during the last quarter. Finally, Truist Financial Corp acquired a new position in Alphatec during the second quarter worth about $216,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

About Alphatec

(Get Free Report)

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

Read More